A phase 1/2 investigator-initiated study of ImmuniStim in COVID-19 infected patients in the UK
Latest Information Update: 21 Feb 2022
At a glance
- Drugs TCB 007 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2022 According to a TC BioPharm media release, company announcedclosing of $17.5 million initial public offering, Company intends to use the net proceeds from the offering to finance the cost of treating patients under this trial.
- 19 Oct 2021 New trial record
- 13 Oct 2021 According to a TC BioPharm media release, the company has launched this phase 1/2 study. The recruitment in this study is commencing at the Newcastle upon Tyne Hospital under the leadership of Dr Brendon Payne.